Cadrenal Therapeutics Inc. Common Stock (CVKD)
Stock · NASDAQ · Health Care
$1.09as of 10/16/2026
Price chart
Active signals
CVKD Signal Track Record
How signals performed across all stocks →What CVKD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 24 | -2.2% | 46% | October 7, 2026 |
| Bollinger Band Breakdown | 17 | -9.4% | 41% | October 1, 2026 |
| Bollinger Band Breakout | 12 | +0.7% | 50% | April 22, 2026 |
| Any 20-session window (baseline) | -5.1% | 42% |
Computed by MarketWall from daily closing prices since November 3, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CVKD
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventric…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 5
- Website
- www.cadrenal.com/
Fundamentals
- 1-day range
- $0.9612$1.12
- Market cap
- $6.67M
- P/E (trailing)
- —
- P/E (forward)
- -0.32
- EPS (trailing)
- $-4.92
- Dividend yield
- —
- Beta
- 1.92
- Avg. volume
- 468.7K
Forecasts
3 analyst ratings
Cadrenal Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- CVKDCadrenal Therapeutics Inc. Common Stock$1.09▲ 12.37%Market cap $6.67MP/E —$0.8163$14.35
- IMNNImunon Inc. Common Stock$1.02▼ 3.77%Market cap $6.64MP/E —$0.96$5.29
- ALZNAlzamend Neuro Inc. Common Stock$1.3▲ 1.56%Market cap $6.61MP/E —$0.84$2.68
- FBLGFibroBiologics Inc. Common Stock$0.971▼ 2.90%Market cap $6.79MP/E —$0.62$9.65
- XBIOXenetic Biosciences Inc. Common Stock$1.99▼ 1.00%Market cap $6.53MP/E —$1.87$5.28
- XTLBXTL Biopharmaceuticals Ltd. American Depositary Shares$1.96▲ 2.62%Market cap $7.05MP/E —$1.6$11.8
- ENVBEnveric Biosciences Inc. Common Stock$1.38▼ 0.72%Market cap $6.28MP/E —$1.17$13.25
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CVKD Cadrenal Therapeutics Inc. Common Stock | $6.67M | — | $1.09 | ▲ 12.37% | $0.8163$14.35 |
| IMNN Imunon Inc. Common Stock | $6.64M | — | $1.02 | ▼ 3.77% | $0.96$5.29 |
| ALZN Alzamend Neuro Inc. Common Stock | $6.61M | — | $1.3 | ▲ 1.56% | $0.84$2.68 |
| FBLG FibroBiologics Inc. Common Stock | $6.79M | — | $0.971 | ▼ 2.90% | $0.62$9.65 |
| XBIO Xenetic Biosciences Inc. Common Stock | $6.53M | — | $1.99 | ▼ 1.00% | $1.87$5.28 |
| XTLB XTL Biopharmaceuticals Ltd. American Depositary Shares | $7.05M | — | $1.96 | ▲ 2.62% | $1.6$11.8 |
| ENVB Enveric Biosciences Inc. Common Stock | $6.28M | — | $1.38 | ▼ 0.72% | $1.17$13.25 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Cadrenal Therapeutics Announces Strategic Review Including Potential Asset Sales Or Merger, Says It Received 'Strong Interest' From Potential Partnersbenzinga · 10/7/2026
- Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory TherapeuticsYahoo · 10/7/2026
- Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor ConferenceYahoo · 9/21/2026
Insider Activity
Insider Actions →- Quang X. Pham · June 29, 2026 · Sale7.4K @ $3.03
- Quang X. Pham · June 26, 2026 · Sale9.0K @ $3.05
- Quang X. Pham · June 25, 2026 · Sale2.1K @ $3
- Quang X. Pham · June 23, 2026 · Sale2.3K @ $3.2
- Quang X. Pham · June 22, 2026 · Sale9.2K @ $3.55
- Quang X. Pham · June 17, 2026 · Sale513 @ $3.16
- Quang X. Pham · June 16, 2026 · Sale3.6K @ $3.18
- Quang X. Pham · June 15, 2026 · Sale3.7K @ $3.58
- Quang X. Pham · June 12, 2026 · Sale13.0K @ $3.94
- Quang X. Pham · June 11, 2026 · Sale1.5K @ $4.12
- Quang X. Pham · June 10, 2026 · Sale3.5K @ $4.21
- Quang X. Pham · June 9, 2026 · Sale13.0K @ $4.06
- Quang X. Pham · June 8, 2026 · Sale5.9K @ $4.38
- Quang X. Pham · June 5, 2026 · Sale2.1K @ $4.42
- Quang X. Pham · June 4, 2026 · Sale3.9K @ $4.41
Institutional Ownership
March 31, 2026
- Total shares held
- 75.1K
- Total value held
- $377.0K
- Institutional holders
- 15
- Unknown45.2K
- Unknown21.6K
- Unknown5.5K
- Unknown1.5K
- Unknown393
- Unknown300
- Unknown200
- Unknown150
- Unknown100
- Unknown99
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Cadrenal hires Tungsten Advisors to drive strategic process
Cadrenal Therapeutics has appointed Tungsten Advisors to lead a formal strategic process aimed at maximizing the value of its orphan thrombo‑inflammatory drug portfolio. The move signals a focus on unlocking potential upside for the company’s niche therapeutics. Investors may view this as an effort to improve the company’s valuation prospects. The stock remains near its 12‑touch support level at $1.05.
Cadrenal hires Tungsten Advisors to drive strategic process. Cadrenal Therapeutics has appointed Tungsten Advisors to lead a formal strategic process aimed at maximizing the value of its orphan thrombo‑inflammatory drug portfolio. The move signals a focus on unlocking potential upside for the company’s niche therapeutics. Investors may view this as an effort to improve the company’s valuation prospects. The stock remains near its 12‑touch support level at $1.05.